Akums Drugs & Pharmaceuticals reported a strong start to FY27 with Q1 FY27 revenue increasing by 13.9% year-on-year to INR 1,167 crore. Operating EBITDA saw a significant jump of 35.4% to INR 175 crore. The company highlighted healthy growth in its CDMO segment, driven by volume and API price improvements, and expressed confidence in continued robust performance across various business segments.
Akums Drugs & Pharmaceuticals Reports Strong Q1 FY27 Financials
Akums Drugs & Pharmaceuticals announced its financial results for the first quarter of FY27 (ended June 30, 2026), reporting a healthy increase in both revenue and profitability. The company’s operating revenue for the quarter stood at INR 1,167 crore, marking a year-on-year increase of 13.9%. This represents a sequential growth from INR 1,158 crore in Q4 FY26 and INR 1,024 crore in Q1 FY26.
EBITDA and Profit Growth
Operating EBITDA for the quarter was reported at INR 175 crore, an impressive 35.4% increase compared to the same period last year. The EBITDA margin improved to 15%, up 238 basis points year-on-year. Including other income, EBITDA stood at INR 205 crore, up 31.7% year-on-year. Profit After Tax (PAT) saw a substantial rise of 56.1% year-on-year, reaching INR 101 crore.
Segment Performance Highlights
The CDMO segment continued its strong performance, with revenue growing 18.6% year-on-year to INR 964 crore. This growth was attributed to healthy volume expansion and improved API prices. The API segment showed a decline in revenue but improved its EBITDA, with losses narrowing significantly compared to previous quarters. The domestic branded formulation segment, Akumentis, registered a 7% revenue growth. The international branded formulation business experienced a slight decline but is expected to return to growth.
Strategic Initiatives and Outlook
The company recently announced the acquisition of Oriflame India’s manufacturing business, expanding its footprint in skin care cosmetics and wellness products. Akums expressed confidence in its strategy to tap into niche formulations and expand its market presence. The management anticipates a robust operating performance for FY27, with positive growth expected across its CDMO, API, and branded formulation segments. The company also maintains a healthy balance sheet with a cash surplus of INR 1,616 crore.
Source: BSE
